Newsletter

Biotech Stocks

Here Are 4 Dogs of the ASX that will Bounce Back With a Vengeance in FY26, and 4 That Won’t

Have you ever heard the term Dogs of the ASX? It can either allude to the worst stocks in the ASX generally, or perhaps the investment strategy of buying these worst performing shares at the start of a new year (either a calendar or financial year), thinking they will rebound. Many will be considering this strategy,…

ByNick SundichJuly 14, 2025

SDI (ASX:SDI): Will slow and steady win the race?

If you're looking for a stock that'll make you a fortune, SDI (ASX:SDI) might not be the best one for you. But if you just want a stock that has little downside risk, it might be more appropriate - but we can only say might. Given the record of dental stocks on the ASX, you might…

ByNick SundichJuly 11, 2025

Botanix Pharmaceuticals (ASX:BOT): Did it deserve to crash over 50% earlier this week?

Botanix Pharmaceuticals (ASX:BOT) crashed over 50% back on Tuesday after an update that left investors disappointed. A crash of this magnitude would suggest the FDA knocked back its drug or that it failed a clinical trial. With Botanix having commercialised its treatment, neither was the case, so it'd have to be a pretty bad sales update.…

ByNick SundichJuly 9, 2025

Here are Our 11 Top ASX Stocks to Buy in FY26: 1 From Each Sector!

It is a New Financial Year, so it's time to outline 11 Top ASX Stocks to Buy in FY26. Why 11 you might ask? Because 11 is the number of 'GICS' (Global Industry Classification Sectors) on the ASX, and we're picking one from each sector. Our 11 Top ASX Stocks to Buy in FY26! Energy: Ampol…

ByNick SundichJuly 7, 2025

Tetratherix Hits the ASX: What Investors Need to Know About This Fresh Life Sciences Listing

Tetratherix Limited (ASX: TTX) officially began trading on the Australian Securities Exchange following a successful initial public offering that raised A$25 million through the issuance of 8.68 million shares at A$2.88 each. The float places the company’s market capitalisation at approximately A$145 million. Importantly, the capital raised leaves Tetratherix with an estimated cash balance of…

ByUjjwal MaheshwariJuly 1, 2025

Here’s why it is a terrific time to look at ASX biotech small caps, and 4 worth considering for FY26

It's been a tough few years for ASX biotech small caps. Even in the last 18 months, the market recovered from post-COVID inflation small cap biotechs have been left behind. The ASX 200 Healthcare Index is down 7% in 2025 whilst the broader ASX 200 is up 4% (yes, even with the crash due to…

ByNick SundichJuly 1, 2025

When investors are in a risk off mindset: Here are the 5 moves they usually make and why

Israel’s strikes on Iran, and the subsequent responses, led to the typical "risk off" moves professional investors usually make when faced with uncertainty. But what exactly does "risk off" mean and how relevant is it for retail investors? Should you be risk off too or should you ride out geopolitical uncertainty? Few would've predicted Israel would've…

ByNick SundichJune 18, 2025

Monash IVF (ASX:MVF): Just when you thought a difficult 5 year span was over…

In the decade since fertility provider Monash IVF (ASX:MVF) listed, it was not an easy journey. Only a few months ago, we thought the business had turned a corner and many others did too. Then...trouble struck. Is this a buy the dip opportunity, or a risk of catching a falling knife? Introduction to Monash IVF Monash…

ByNick SundichJune 10, 2025

How to stop the ASX decline? ASIC and investors have some radical ideas

Addressing the ASX decline is a question that has been considered for many months now. In 2023-24, more companies left the ASX in the past 2 years than any 2 year period since the 1990s recession - whether being brought out by private equity or a big industry player, delisting to a penny stock exchange…

ByNick SundichJune 6, 2025

Proteomics’ PromarkerD test for DKD has been launched in Australia, and two more tests will launch later in 2025

2025 has been, and will continue to be, a big year for Proteomics, which has just launched PromarkerD onto the Australian market. Before this year is over, the company anticipates launching another 2 tests - PromarkerEndo and PromarkerEso; and is eyeing off the US market too. Recap of Proteomics (ASX:PIQ) For investors that are new to…

ByNick SundichMay 28, 2025

the Kick-ass Multipurpose WordPress Theme

Biotech Stocks

Here Are 4 Dogs of the ASX that will Bounce Back With a Vengeance in FY26, and 4 That Won’t

SDI (ASX:SDI): Will slow and steady win the race?

Botanix Pharmaceuticals (ASX:BOT): Did it deserve to crash over 50% earlier this week?

Here are Our 11 Top ASX Stocks to Buy in FY26: 1 From Each Sector!

Tetratherix Hits the ASX: What Investors Need to Know About This Fresh Life Sciences Listing

Here’s why it is a terrific time to look at ASX biotech small caps, and 4 worth considering for FY26

When investors are in a risk off mindset: Here are the 5 moves they usually make and why

Monash IVF (ASX:MVF): Just when you thought a difficult 5 year span was over…

How to stop the ASX decline? ASIC and investors have some radical ideas

Proteomics’ PromarkerD test for DKD has been launched in Australia, and two more tests will launch later in 2025

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Biotech Stocks

Stocks in Spotlight

Add Your Heading Text Here